PA
AZN icon

Procyon Advisors’s AstraZeneca AZN Stock Holding History

Procyon Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$919K Sell
4,845
-145
-3% -$27.3K 0.04% 286
2026
Q1 		$984K Buy
4,990
+1,034
+26% +$199K 0.05% 270
2025
Q4 		$727K Buy
3,956
+1,787
+82% +$313K 0.04% 299
2025
Q3 		$333K Sell
2,169
-262
-11% -$39.7K 0.02% 388
2025
Q2 		$340K Sell
2,431
-16,496
-87% -$2.31M 0.03% 350
2025
Q1 		$2.78M Buy
18,927
+2,079
+12% +$301K 0.17% 130
2024
Q4 		$2.21M Buy
16,848
+1,921
+13% +$269K 0.14% 149
2024
Q3 		$2.33M Buy
14,927
+1,635
+12% +$264K 0.16% 144
2024
Q2 		$2.07M Buy
13,292
+1,017
+8% +$153K 0.15% 148
2024
Q1 		$1.66M Buy
12,275
+1,719
+16% +$228K 0.13% 170
2023
Q4 		$1.42M Buy
10,556
+7,985
+311% +$1.04M 0.12% 178
2023
Q3 		$348K Buy
2,571
+697
+37% +$95.2K 0.04% 362
2023
Q2 		$268K Buy
1,874
+12
+0.6% +$1.77K 0.03% 375
2023
Q1 		$258K Sell
1,862
-298
-14% -$40.1K 0.04% 330
2022
Q4 		$293K Buy
2,160
+47
+2% +$5.89K 0.05% 298
2022
Q3 		$232K Sell
2,113
-12
-0.6% -$1.52K 0.06% 282
2022
Q2 		$281K Sell
2,125
-85
-4% -$11.2K 0.06% 261
2022
Q1 		$293K Sell
2,210
-426
-16% -$51.1K 0.06% 268
2021
Q4 		$307K Buy
2,636
+203
+8% +$23.9K 0.07% 252
2021
Q3 		$292K Sell
2,433
-36
-1% -$4.19K 0.07% 243
2021
Q2 		$296K Buy
2,469
+55
+2% +$6.03K 0.08% 221
2021
Q1 		$240K Hold
2,414
– – 0.11% 216
2020
Q4 		$241K Buy
2,414
+120
+5% +$12.7K 0.12% 204
2020
Q3 		$251K Sell
2,294
-634
-22% -$70.5K 0.14% 165
2020
Q2 		$310K Sell
2,928
-121
-4% -$12.5K 0.16% 125
2020
Q1 		$272K Sell
3,049
-50
-2% -$4.71K 0.18% 111
2019
Q4 		$309K Buy
+3,099
New +$292K 0.19% 109

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Procyon Advisors's AZN Position: Q2 2026 in Review

Procyon Advisors reduced its AstraZeneca (AZN) stake by 2.9% in Q2 2026, selling an estimated $27.3K and leaving 4,845 shares worth $919K. The position accounts for 0.04% of the portfolio, ranked #286.

Procyon Advisors first reported a position in AZN in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.78M in Q1 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Procyon Advisors held 4,845 shares of AstraZeneca worth $919K as of Q2 2026.
  • Procyon Advisors sold 145 AstraZeneca shares in Q2 2026, an estimated $27.3K.
  • AstraZeneca made up 0.04% of Procyon Advisors's portfolio in Q2 2026, its #286 holding.
  • Procyon Advisors first reported a position in AstraZeneca in Q4 2019 and has held it in 27 quarters since.
  • Procyon Advisors's AstraZeneca position peaked at $2.78M in Q1 2025.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Procyon Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.